Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life against seasonal vs perennial allergens: ESPRINT-15 modified in the pediatric population.
López-Rodríguez R, Sanz JH, Rial MJ, Pérez BV, Hernández JS, López-Silvarrey A, Alonso MV, Vera CG, Guerrero MTC, Velillas JJL, Hernández MIM, Malo MJS, Lombardía CR. López-Rodríguez R, et al. Among authors: perez bv. Allergol Immunopathol (Madr). 2022 Sep 1;50(5):16-22. doi: 10.15586/aei.v50i5.624. eCollection 2022. Allergol Immunopathol (Madr). 2022. PMID: 36086959
Clinical and diagnostic features of 33 patients with aquagenic urticaria.
López-Rodríguez R, Castelo Galvan H, Perez-Quintero O, Rial Prado MJ, Gomez-Fariñas C, Parra Arrondo A, Hernandez JS, Veleiro Pérez B. López-Rodríguez R, et al. J Allergy Clin Immunol Pract. 2023 Oct;11(10):3272-3274. doi: 10.1016/j.jaip.2023.06.029. Epub 2023 Jun 24. J Allergy Clin Immunol Pract. 2023. PMID: 37364666 No abstract available.
Hypersensitivity to paroxetine.
Mera MT, Pérez BV, Fernández RO, Iglesias JF. Mera MT, et al. Among authors: perez bv. Allergol Immunopathol (Madr). 2006 May-Jun;34(3):125-6. doi: 10.1016/s0301-0546(06)73527-3. Allergol Immunopathol (Madr). 2006. PMID: 16858890
Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.
Caronna E, Gallardo VJ, Egeo G, Vázquez MM, Castellanos CN, Membrilla JA, Vaghi G, Rodríguez-Montolio J, Fabregat Fabra N, Sánchez-Caballero F, Jaimes Sánchez A, Muñoz-Vendrell A, Oliveira R, Gárate G, González-Osorio Y, Guisado-Alonso D, Ornello R, Thunstedt C, Fernández-Lázaro I, Torres-Ferrús M, Alpuente A, Torelli P, Aurilia C, Pére RL, Castrillo MJR, Icco R, Sances G, Broadhurst S, Ong HC, García AG, Campoy S, Sanahuja J, Cabral G, Beltrán Blasco I, Waliszewska-Prosół M, Pereira L, Layos-Romero A, Luzeiro I, Dorado L, Álvarez Escudero MR, May A, López-Bravo A, Martins IP, Sundal C, Irimia P, Lozano Ros A, Gago-Veiga AB, Juanes FV, Ruscheweyh R, Sacco S, Cuadrado-Godia E, García-Azorín D, Pascual J, Gil-Gouveia R, Huerta-Villanueva M, Rodriguez-Vico J, Viguera Romero J, Obach V, Santos-Lasaosa S, Ghadiri-Sani M, Tassorelli C, Díaz-de-Terán J, Díaz Insa S, Oria CG, Barbanti P, Pozo-Rosich P; EUREkA study group. Caronna E, et al. J Neurol Neurosurg Psychiatry. 2024 Sep 17;95(10):927-937. doi: 10.1136/jnnp-2023-333295. J Neurol Neurosurg Psychiatry. 2024. PMID: 38777579